Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.

about

Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats.Pulmonary hypertension and cardiac anesthesia: Anesthesiologist's perspective.

P2860

Q50416961-5FB6DCA9-6BB0-4896-9DCC-4531CCDC9E5C Q55214462-E7417D67-CCC5-4F11-9C53-5A90442447B4

P2860

Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.

Item

http://www.wikidata.org/entity/Q39317922

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Selexipag, a selective prostac ...... ension: a pharmacology review.

@en

Selexipag, a selective prostac ...... ension: a pharmacology review.

@nl

type

Item

label

Selexipag, a selective prostac ...... ension: a pharmacology review.

@en

Selexipag, a selective prostac ...... ension: a pharmacology review.

@nl

prefLabel

Selexipag, a selective prostac ...... ension: a pharmacology review.

@en

Selexipag, a selective prostac ...... ension: a pharmacology review.

@nl

P1476

Selexipag, a selective prostac ...... ension: a pharmacology review.

@en

P2093

Jesús Honorato Pérez

http://www.w3.org/2001/XMLSchema#string

P2860

Management of pulmonary arterial hypertension

The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension

Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Inhaled iloprost for severe pulmonary hypertension.

Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.

Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.

Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.

International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress

P304

753-762

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17512433.2017.1322900

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28524738

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

arterial hypertension

Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.

about

P2860

P2860

Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921